Jupiter news, features and articles
Jupiter is so large that it's known as the king of planets. At Live Science, we bask in its gassy glory by publishing facts and findings about the giant, including coverage of how Jupiter's unearthly beauty was revealed in a gorgeous true-color image, how scientists found remains of cannibalized baby planets in Jupiter's cloud-covered belly and how the mystery of Jupiter's powerful X-ray auroras was finally solved. So, if you want to learn more about our solar system's largest planet, check out the latest Jupiter news, features and articles by our expert writers and editors.
—Jupiter: Facts about the biggest planet in our solar system
—Could a spaceship fly through a gas giant like Jupiter?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
29 minutes ago
- Medscape
Ileal Resection Tied to Higher CRC Risk in Crohn's Disease
TOPLINE: Patients with Crohn's disease who undergo terminal ileum resection have a significantly higher risk of developing colorectal cancer (CRC) and colorectal polyps than those who do not undergo resection. METHODOLOGY: Up to 70% of patients with Crohn's disease undergo ileocecal resection, which increases colonic bile acid flux exposure and potentially promotes induction of tumorigenic pathways. However, the direct impact of terminal ileum resection on CRC risk in Crohn's disease remains uncertain. Researchers conducted a retrospective cohort study (2005-2024) using U.S. electronic health record data from adults with Crohn's disease to assess the association between terminal ileum resection and CRC risk. The primary outcome was the risk for CRC in patients with and without terminal ileum resection. Secondary outcomes included the risk for CRC based on biologics use and colonic involvement, and risk for benign colonic polyps. TAKEAWAY: Researchers included 13,617 patients with Crohn's disease who underwent terminal ileum resection (mean age, 39.5 years; 51.3% female) and an equal number of matched controls without resection. Terminal ileum resection was associated with a significantly higher risk for CRC (adjusted hazard ratio [aHR], 2.58; P < .001), which was consistent in both men (aHR, 4.23; P < .001) and women (aHR, 2.43; P < .01). Elevated CRC risk persisted regardless of colonic involvement (P < .01). CRC risk did not significantly differ between patients who received biologic therapy and those who were biologic naive. Patients with resection also had a higher risk for nonmalignant colonic polyps (aHR, 1.11; P < .01), which was consistent in both men and women (P < .01 for both). IN PRACTICE: "Our findings highlight the need to reassess CRC surveillance strategies in patients with [Crohn's disease] post-[terminal ileum] resection. While current guidelines focus on inflammation-related risk, our results suggest that surgical history itself is an independent risk factor," the authors concluded. SOURCE: This study was led by Inas Mikhail, MD, Mayo Clinic, Jacksonville, Florida, and Omar Al Ta'ani, MD, Allegheny Health Network, Pittsburgh, Pennsylvania. It was published online in Inflammatory Bowel Diseases. LIMITATIONS: The retrospective design may introduce biases related to reporting, selection, and follow-up. Residual confounding factors may have persisted despite propensity score matching. Due to a lack of data on bile acid profile and inflammatory burden, it could not be determined whether dysregulation of bile acids was directly involved in CRC risk. DISCLOSURES: This study authors reported no specific funding or conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
Semaglutide Has Found Its STRIDE
Key results and new insights from the STRIDE trial and the evolving role of GLP-1 receptor agonist (RA) therapy in type 2 diabetes (T2D) and peripheral arterial disease (PAD) were discussed during a symposium at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, which I was fortunate to attend. A Common Comorbidity T2D and PAD are not strangers to one another; patients with T2D are twice as likely to develop PAD compared with the general population. PAD has been shown to be the most common initial manifestation of cardiovascular disease in T2D. Moreover, patients with diabetes foot complications fear amputation and infection more than death. However, PAD is underrecognized in T2D; only around 20% of patients present with the classical symptoms of intermittent claudication (IC). PAD also has insidious onset: Patients experience slow functional decline and leg discomfort, which is often not recognized as PAD by healthcare professionals or patients. T2D and PAD are growing in incidence and share many risk factors, including obesity. A recent systematic literature review exploring the epidemiology and burden of PAD in T2D found that 12.5%-22% of patients with T2D had comorbid PAD. Furthermore, patients with T2D and PAD have a very high risk for major lower-limb complications and major adverse cardiovascular events, including all-cause and cardiovascular mortality. Unsurprisingly, PAD was associated with poor quality of life and significant healthcare use and costs. Notably, the ADA 2025 Standards of Medical Care in Diabetes now recommends screening for PAD using ankle-brachial index (ABI) testing in asymptomatic patients with diabetes aged > 65 years, microvascular disease in any location, or foot complications or any end-organ damage from diabetes if a PAD diagnosis would change management. PAD screening should also be considered in patients with diabetes duration > 10 years and high cardiovascular risk. PAD in T2D is often recalcitrant to surgical intervention because it tends to affect the distal vasculature (that is, the infrapopliteal vessels). These lesions are less amenable to traditional revascularization procedures such as femoropopliteal bypass and stenting. Unfortunately, this circumstance often leaves patients with T2D and PAD with persistent debilitating symptoms and few surgical options. Many international medical guidelines have class I recommendations to consider SGLT2 inhibitors and GLP-1 RAs for patients with T2D and atherosclerotic cardiovascular disease, though not specifically PAD. The only class I recommendation in PAD is for cilostazol for improving claudication symptoms. Cilostazol is a phosphodiesterase 3 inhibitor that promotes vasodilation and increased blood flow, which can improve symptoms of IC (but not cardiovascular outcomes). A recent Cochrane review found that cilostazol resulted in only a 40 m improvement in absolute claudication distance. From my clinical experience, cilostazol is often poorly tolerated (headache and diarrhea are common). It is contraindicated in heart failure, which frequently occurs with PAD. STRIDE Results The randomized controlled STRIDE trial was published in the Lancet in May 2025 and explored the impact of subcutaneous semaglutide (1 mg weekly) plus standard of care, compared with placebo, on walking capacity in patients with symptomatic PAD and T2D. In essence, STRIDE has laid the foundation for a paradigm shift in how we use GLP-1 RAs for symptomatic PAD. The trial recruited 792 patients with T2D and Fontaine stage IIa PAD. Fontaine stage IIa is early-stage symptomatic PAD, in which patients experience symptoms of IC after walking more than 200 m. Mean ABI was ≤ 0.9 in all participants; a normal ABI is typically 0.90-1.30 and indicates normal blood flow to the lower limbs. One-quarter of participants were female, and median age was 68 years. Obesity was not a criterion for study enrollment; 35% of participants had a BMI < 27. The primary outcome of the study was maximum walking distance after 52 weeks compared with baseline. STRIDE achieved its primary outcome. Subcutaneous semaglutide was associated with a significantly increased maximum walking distance (40 m improvement on a 12% incline, which is equivalent to 80 m improvement on a flat surface). This improvement is double that associated with cilostazol and, importantly, was confirmed to be clinically meaningful. The researchers also observed significantly improved symptoms and quality of life, as evidenced by improvements in the VascuQoL questionnaire. Notably, the reported improvements in ABI and disease progression confirm the vascular benefits of semaglutide. Encouragingly, clinical benefits persisted even 5 weeks after stopping semaglutide therapy. The treatment's safety profile was consistent with previous semaglutide trials, and no unexpected safety findings emerged. New data presented and simultaneously published in Diabetes Care confirmed that the effect of semaglutide on maximum walking distance was consistent, irrespective of T2D characteristics; benefits were independent of baseline diabetes duration, BMI, HbA1c, or concomitant use of sodium/glucose cotransporter 2 inhibitors or insulin. Functional benefits did not appear to correlate with weight loss or glycemic improvement, again highlighting the vascular benefits of semaglutide in reducing atherosclerosis, possibly through an anti-inflammatory effect. In conclusion, STRIDE increases the suite of recognized cardiometabolic and renal benefits of semaglutide by adding improved walking capacity, quality of life, and disease progression for patients with T2D and PAD. During my resident year as a junior doctor, my vascular consultant always reminded me of the core management of PAD in five words: 'stop smoking and keep walking.' While this remains the cornerstone of management 25 years later, semaglutide is now well positioned as a foundational therapy to improve quality and quantity of life in patients with T2D and PAD.
CNN
an hour ago
- CNN
The link between cancer and exercise that patients should know
We all know that regular exercise has many benefits, including reducing the risk of chronic diseases such as diabetes and heart disease. Exercise also improves outcomes in patients with cancer, according to a new study published in the New England Journal of Medicine. Patients with cancer who participated in a structured exercise program in a randomized-controlled trial lived longer without cancer recurrence and had a lower risk of dying within the trial period compared with people in the control group. I was curious why and how exercise reduces cancer risk, and what everyone should know about incorporating exercise programs in their lives. To find out, I spoke with CNN wellness expert Dr. Leana Wen. Wen is an emergency physician and adjunct associate professor at George Washington University. She previously served as Baltimore's health commissioner. CNN: Why are the results of this study so important? Dr. Leana Wen: Previous research suggested that exercise could be beneficial for cancer survivors, but this is the first randomized trial that demonstrates exercise after cancer treatment can reduce recurrence and improve survival. Researchers recruited nearly 900 patients from 55 cancer centers across six countries who had been treated for either stage III or high-risk stage II colon cancer. Even after cancer treatments such as surgery followed by chemotherapy, colon cancer comes back in an estimated 30% of patients, according to the American Society of Clinical Oncology. Many patients with recurrence of their colon cancer end up dying from their disease. The patients in the new study were randomized to two groups. The control group received standard health education materials promoting healthy eating and physical activity. This is the current standard-of-care that is provided to patients in remission from their cancer. The other group participated in a structured exercise program that involved working with a health coach for physical activity guidance and supervised exercise sessions. During the initial six months, patients had twice-a-month coaching sessions. After that period, they met with coaches once a month, with extra sessions available if needed. Participants randomized to the structured exercise group had significantly higher improvements in physical function as measured by distance they could walk in six minutes and predicted VO2 max (your oxygen uptake), both indicators of cardiovascular fitness. The two groups were followed for an average of about eight years. During this period, 131 patients in the control group had recurrence of their cancer, compared with 93 in the structured exercise group. In the control group, 66 people died, compared with 41 in the structured exercise group. People in the structured exercise group had a 28% lower risk of developing recurrent or new cancers compared with those who followed standard-of-care protocols. Members of the exercise group also had a 37% lower risk of death in the trial period. This study is important because its rigorous methodology confirms what previous research had suggested: Exercise extends disease-free survival for patients with cancer and should be incorporated as part of holistic treatment for patients to reduce their risk of recurrent and new cancers. CNN: How might results of the study change treatment for patients with cancer? Wen: Imagine if there were a clinical trial for a new drug that found it lowered the risk of developing recurrent or new cancers by 28% and lowered the risk of death in the trial period by 37%. Patients and doctors would hail this as a tremendous development and would be eager to try this new therapeutic. That's the magnitude of the findings in this study. I believe they have the potential to substantially change cancer treatment protocols. Currently, after patients receive treatments such as surgery, chemotherapy and radiation, they are given advice to exercise, but many probably do not engage the services of a health coach or trainer. Their oncologists and primary care doctors may not be asking about their physical activity regimen during follow-up care. I hope this will change, in view of these results. Patients can be counseled to have an 'exercise prescription,' and health care providers can follow up to track their exercise activity. Perhaps insurance companies could even consider reimbursement for a health coach for patients with cancer; this could be seen as an investment to reduce the need for costlier chemotherapy and other treatments down the line. CNN: Why and how does exercise reduce cancer risk? Wen: Population studies have long shown that regular physical activity is associated with lower risks of developing certain cancers. There are several theories as to why this is the case. One is that physical activity helps people stay at a healthy weight, which is notable because obesity is a risk factor for developing some cancers. In addition, exercise is thought to help regulate some hormones that are implicated in cancer development and to reduce inflammatory response that could also be involved in cancer. CNN: How much exercise do people need? Wen: The US Centers for Disease Control and Prevention recommends that adults participate in at least 150 minutes of moderate to high-intensity exercise per week. For someone who is exercising five times a week, that's about 30 minutes at a time of exercises such as a brisk walk or jog, riding a bike or swimming. The benefits of these exercise minutes are cumulative, meaning that individuals don't need to do them all at once to have an effect. People who are unable to commit a period of time to exercise could consider how they could incorporate physical activity into their daily routines. Could they take the stairs instead of the elevator at work? If they do this five times a day, that could be as many as 10 minutes of exercise. Could they take a 10-minute phone meeting while walking in their neighborhood instead of sitting at a desk? Could they park a bit farther away to get in a few more minutes of physical activity? Small changes add up. CNN: What other advice do you have for people who want to begin exercise programs? Wen: Many studies show that while it's ideal to get the recommended 150 minutes a week of exercise, there is a significant benefit from even a small amount of physical activity. The best advice I can offer is to not let the perfect be the enemy of the good — start with what you can. For instance, consider the idea of 'exercise snacks,' or bursts of activity that could be as short in duration as 15 or 30 seconds. These are as simple as doing a few squats or performing household chores. Getting up from your chair and just moving around helps, which is especially important for desk-bound workers who need additional exercise to counter the negative health impacts of sitting. Sign up for CNN's Fitness, But Better newsletter series. Our seven-part guide will help you ease into a healthy routine, backed by experts.
